[1. Brooks-Worrell B, Palmer JP. Is diabetes mellitus a continuous spectrum? Clin Chem 2011; 57(2):158-61. DOI: 10.1373/clinchem.2010.14827010.1373/clinchem.2010.14827021068340]Search in Google Scholar
[2. Lin J, Zhou ZG, Wang JP, Zhang C, Huang G. From Type 1, through LADA, to type 2 diabetes:a continuous spectrum? Ann N Y Acad Sci 2008 Dec; 1150:99-102. DOI: 10.1196/annals.1447.03610.1196/annals.1447.03619120276]Search in Google Scholar
[3. Fourlanos S, Harrison LC, Colman PG. The accelerator hypothesis and increasing incidence of type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2008; 15(4):321-5. DOI: 10.1097/MED.0b013e3283073a5a10.1097/MED.0b013e3283073a5a18594271]Search in Google Scholar
[4. Wilkin TJ. The accelerator hypothesis:a review of the evidence for insulin resistance as the basis for type I as well as type II diabetes. Int J Obes (Lond) 2009; 33(7):716-26. DOI: 10.1038/ijo.2009.9710.1038/ijo.2009.9719506563]Search in Google Scholar
[5. Brooks-Worrell B, Narla R, Palmer JP. Islet Autoimmunity in Phenotypic Type 2 Diabetes Patients. Diabetes Obes Metab 2013; 15:137–40. DOI: 10.1111/dom.1216710.1111/dom.12167426053424003930]Search in Google Scholar
[6. Welch BJ, Zib I. Case Study:Diabetic Ketoacidosis in Type 2 Diabetes: “Look Under the Sheets”. Clinical Diabetes 2004; 22(4):198-200. DOI: 10.2337/diaclin.22.4.19810.2337/diaclin.22.4.198]Search in Google Scholar
[7. de Lusignan S, Khunti K, Belsey J, Hattersley A, van Vlymen J, Gallagher H, et al. A method of identifying and correcting miscoding, misclassification and misdiagnosis in diabetes:a pilot and validation study of routinely collected data. Diabet Med 2010; 27(2):203-9. DOI: 10.1111/j.1464-5491.2009.02917.x10.1111/j.1464-5491.2009.02917.x20546265]Search in Google Scholar
[8. de Lusignan S, Sadek N, Mulnier H, Tahir A, Russell-Jones D, Khunti K. Miscoding, misclassification and misdiagnosis of diabetes in primary care. Diabet Med 2012; 29(2):181-9. DOI: 10.1111/j.1464-5491.2011.03419.x10.1111/j.1464-5491.2011.03419.x21883428]Search in Google Scholar
[9. Stone MA, Camosso-Stefinovic J, Wilkinson J, de Lusignan S, Hattersley AT, Khunti K. Incorrect and incomplete coding and classification of diabetes:a systematic review. Diabet Med 2010; 27(5):491-7. DOI: 10.1111/j.1464-5491.2009.02920.x10.1111/j.1464-5491.2009.02920.x20536944]Search in Google Scholar
[10. Tripathi A, Rizvi AA, Knight LM, Jerrell JM. Prevalence and impact of initial misclassification of pediatric type 1 diabetes mellitus. South Med J 2012; 105(10):513-7. DOI: 10.1097/SMJ.0b013e318268ca6010.1097/SMJ.0b013e318268ca6023038480]Search in Google Scholar
[11. Maraschin Jde F. Classification of diabetes. Adv Exp Med Biol 2012; 771:12-19.10.1007/978-1-4614-5441-0_223393666]Search in Google Scholar
[12. Leslie RD, Kolb H, Schloot NC, Buzzetti R, Mauricio D, De Leiva A, et al. Diabetes classification:grey zones, sound and smoke:Action LADA 1. Diabetes Metab Res Rev 2008; 24(10):511-9. DOI: 10.1002/dmrr.87710.1002/dmrr.87718615859]Search in Google Scholar
[13. Sobngwi E, Gautier JF. Adult-onset idiopathic Type I or ketosis-prone Type II diabetes:evidence to revisit diabetes classification. Diabetologia 2002; 45(2):283-5. DOI: 10.1007/s00125-001-0739-810.1007/s00125-001-0739-811935161]Search in Google Scholar
[14. Cernea S, Raz I, Herold KC, Hirshberg B, Roep BO, Schatz DA, et al; D-Cure Workshop. Challenges in developing endpoints for type 1 diabetes intervention studies. Diabetes Metab Res Rev 2009; 25(8):694-704. DOI: 10.1002/dmrr.100210.1002/dmrr.100219771545]Search in Google Scholar
[15. Bergman RN, Ader M, Huecking K, Van Citters G. Accurate assessment of beta-cell function:the hyperbolic correction. Diabetes 2002; 51 Suppl 1:S212-20. DOI: 10.2337/diabetes.51.2007.S21210.2337/diabetes.51.2007.S212]Search in Google Scholar
[16. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 2013; 30(7):803-17. DOI: 10.1111/dme.1215910.1111/dme.12159374878823413806]Search in Google Scholar
[17. Home P, Riddle M, Cefalu WT, Bailey CJ, Bretzel RG, Del Prato S, et al. Insulin therapy in people with type 2 diabetes:opportunities and challenges? Diabetes Care 2014; 37(6):1499-1508. DOI: 10.2337/dc13-274310.2337/dc13-2743513188424855154]Search in Google Scholar
[18. Hohberg C, Pfutzner A, Forst T, Lubben G, Karagiannis E, Borchert M, et al. Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function:results from the PioSwitch study. Diabetes Obes Metab 2009; 11(5):464–71. DOI: 10.1111/j.1463-1326.2008.00975.x10.1111/j.1463-1326.2008.00975.x19422402]Search in Google Scholar
[19. Lee A, Morley J. Classification of type 2 diabetes by clinical response to metformin–troglitazone combination and C-peptide criteria. Endocr Pract 1999; 5(6):305–13. DOI: 10.4158/EP.5.6.30510.4158/EP.5.6.30515251651]Search in Google Scholar
[20. Araki H, Tanaka Y, Yoshida S, Morita Y, Kume S, Isshiki K, et al. Oral glucose-stimulated serum C-peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment. J Diabetes Investig 2014; 5(4):435-41. DOI: 10.1111/jdi.1216910.1111/jdi.12169421006625411603]Search in Google Scholar
[21. Patel N, Taveira TH, Choudhary G, Whitlatch H, Wu WC. Fasting Serum C-Peptide Levels Predict Cardiovascular and Overall Death in Nondiabetic Adults. J Am Heart Assoc 2012; 1(6):e003152. DOI: 10.1161/JAHA.112.00315210.1161/JAHA.112.003152354068223316320]Search in Google Scholar
[22. Cernea S, Huţanu A, Coroş L, Dobreanu M. Assessment of beta cell function in subjects with newly diagnosed type 2 diabetes. Rev Romana Med Lab 2013; 21(2):145-160. DOI: 10.2478/rrlm-2013-001110.2478/rrlm-2013-0011]Search in Google Scholar
[23. Eckel N, Mühlenbruch K, Meidtner K, Boeing H, Stefan N, Schulze MB. Characterization of metabolically unhealthy normal-weight individuals:Risk factors and their associations with type 2 diabetes. Metabolism 2015; 64(8):862-71. DOI: 10.1016/j.metabol.2015.03.00910.1016/j.metabol.2015.03.00925861921]Search in Google Scholar
[24. Boonchaya-anant P, Apovian CM. Metabolically healthy obesity--does it exist? Curr Atheroscler Rep 2014; 16(10):441. DOI: 10.1007/s11883-014-0441-110.1007/s11883-014-0441-125092577]Search in Google Scholar
[25. Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes:a meta-analysis of prospective cohort studies. Obes Rev 2014; 15(6):504-15. DOI: 10.1111/obr.1215710.1111/obr.12157430949724661566]Search in Google Scholar
[26. Borai A, Livingstone C, Kaddam I, Ferns G. Selection of the appropriate method for the assessment of insulin resistance. BMC Med Res Methodol 2011; 11:158. DOI: 10.1186/1471-2288-11-15810.1186/1471-2288-11-158325820522112229]Search in Google Scholar
[27. Dabelea D, D’Agostino RB Jr, Mason CC, West N, Hamman RF, Mayer-Davis EJ, et al. Development, validation and use of an insulin sensitivity score in youths with diabetes:the SEARCH for Diabetes in Youth study. Diabetologia 2011; 54(1):78-86. DOI: 10.1007/s00125-010-1911-910.1007/s00125-010-1911-9541295020886205]Search in Google Scholar
[28. Geloneze B, Vasques AC, Stabe CF, Pareja JC, Rosado LE, Queiroz EC, et al; BRAMS Investigators. HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome:Brazilian Metabolic Syndrome Study (BRAMS). Arq Bras Endocrinol Metabol 2009; 53(2):281-7. DOI: 10.1590/S0004-2730200900020002010.1590/S0004-2730200900020002019466221]Search in Google Scholar
[29. Ziaee A, Esmailzadehha N, Oveisi S, Ghorbani A, Ghanei L. The threshold value of homeostasis model assessment for insulin resistance in Qazvin Metabolic Diseases Study (QMDS):assessment of metabolic syndrome. J Res Health Sci 2015; 15(2):94-100.]Search in Google Scholar
[30. Bonifacio E. Predicting type 1 diabetes using biomarkers. Diabetes Care 2015; 38(6):989-96. DOI: 10.2337/dc15-010110.2337/dc15-010125998291]Search in Google Scholar
[31. Pihoker C, Gilliam LK, Hampe CS, Lernmark Å. Autoantibodies in Diabetes. Diabetes 2005; 54 (Suppl 2):S52-S61 DOI: 10.2337/diabetes.54.suppl_2.S5210.2337/diabetes.54.suppl_2.S52]Search in Google Scholar
[32. Tooley JE, Herold KC. Biomarkers in type 1 diabetes: application to the clinical trial setting. Curr Opin Endocrinol Diabetes Obes 2014(4); 21:287-92. DOI: 10.1097/MED.000000000000007610.1097/MED.0000000000000076]Search in Google Scholar
[33. Herold KC, Brooks-Worrell B, Palmer J, Dosch HM, Peakman M, Gottlieb P, Reijonen H, Arif S, Spain LM, Thompson C, Lachin JM, et al; Type 1 Diabetes TrialNet Research Group. Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes 2009; 58(11):2588-95. DOI: 10.2337/db09-024910.2337/db09-0249]Search in Google Scholar
[34. Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, et al. Staging Presymptomatic Type 1 Diabetes:A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015; 38(10):1964-74. DOI: 10.2337/dc15-141910.2337/dc15-1419]Search in Google Scholar
[35. Ludvigsson J. The latest pharmacotherapy options for type 1 diabetes. Expert Opin Pharmacother 2014; 15(1):37-49. DOI: 10.1517/14656566.2014.85519710.1517/14656566.2014.855197]Search in Google Scholar
[36. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013; 36 Suppl 2:S127-138. DOI: 10.2337/dcS13-201110.2337/dcS13-2011]Search in Google Scholar
[37. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes:a multicentre randomised parallel-group trial. Lancet 2008; 371(9626):1753-60. DOI: 10.1016/S0140-6736(08)60762-X10.1016/S0140-6736(08)60762-X]Search in Google Scholar
[38. Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996; 45(5):622-6. DOI: 10.2337/diabetes.45.5.622 DOI: 10.2337/diab.45.5.62210.2337/diabetes.45.5.622]Search in Google Scholar
[39. Harrison LB, Adams-Huet B, Raskin P, Lingvay I. β-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care 2012; 35(7):1406-12. DOI: 10.2337/dc11-217010.2337/dc11-2170337958522723578]Search in Google Scholar
[40. Raz I, Mosenzon O. Early insulinization to prevent diabetes progression. Diabetes Care 2013; 36:S190-7. DOI: 10.2337/dcS13-201410.2337/dcS13-2014392080323882045]Search in Google Scholar
[41. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005; 90(1):501-6. DOI: 10.1210/jc.2004-069910.1210/jc.2004-069915483097]Search in Google Scholar
[42. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28(2):187-218. DOI: 10.1210/10.1210/er.2006-003810.1210/10.1210/er.2006-003817353295]Search in Google Scholar
[43. Moon RJ, Bascombe LA, Holt RI. The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being. Diabetes Obes Metab 2007; 9(1):143-5. DOI: 10.1111/j.1463-1326.2006.00599.x10.1111/j.1463-1326.2006.00599.x17199734]Search in Google Scholar
[44. Liu C1, Wu D, Zheng X, Li P, Li L. Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a meta-analysis. Diabetes Technol Ther 2015; 17(2):142-8. DOI: 10.1089/dia.2014.019010.1089/dia.2014.019025369141]Search in Google Scholar
[45. Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia. 2010;53(5):809-20. DOI: 10.1007/s00125-009-1636-910.1007/s00125-009-1636-920057994]Search in Google Scholar
[46. Abdelghaffar S, Attia AM. Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents. Cochrane Database Syst Rev. 2009;(1):CD006691. DOI: 10.1002/14651858.cd006691.pub210.1002/14651858.CD006691.pub2738993219160294]Search in Google Scholar
[47. Munir KM, Davis SN. The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus. Expert Opin Pharmacother. 2015; 16(15):2331-41. DOI: 10.1517/14656566.2015.108450210.1517/14656566.2015.108450226340427]Search in Google Scholar
[48. Traina AN, Lull ME, Hui AC, Zahorian TM, Lyons-Patterson J. Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy. Can J Diabetes 2014; 38(4):269-72. DOI: 10.1016/j.jcjd.2013.10.00610.1016/j.jcjd.2013.10.00624797495]Search in Google Scholar
[49. Crisci I, Aragona M, Politi KS, Daniele G, Del Prato S. GLP-1 receptor agonists in type 1 diabetes:a proof-of-concept approach. Acta Diabetol. 2015; 52(6):1129-1133. DOI: 10.1007/s00592-015-0800-610.1007/s00592-015-0800-626293127]Search in Google Scholar
[50. Ghazi T1, Rink L, Sherr JL, Herold KC. Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges. Diabetes Care 2014; 37(1):210-16. DOI: 10.2337/dc13-116910.2337/dc13-1169396844723939544]Search in Google Scholar
[51. Kielgast U1, Holst JJ, Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes 2011; 60(5):1599-1607. DOI: 10.2337/db10-179010.2337/db10-1790329233621441444]Search in Google Scholar
[52. Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmér M, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005; 19(4):238-46. DOI: 10.1016/j.jdiacomp.2004.12.00310.1016/j.jdiacomp.2004.12.00315993359]Search in Google Scholar
[53. Buzzetti R, Cernea S, Petrone A, Capizzi M, Spoletini M, Zampetti S, et al; DiaPep Trialists Group. C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277:an exploratory study. Diabetes 2011; 60(11):3067-72. DOI: 10.2337/db10-056010.2337/db10-0560319807121896927]Search in Google Scholar